Exploring Creatine's Potential Role in Alleviating Depression Symptoms

The Uncommon Link Between Creatine and Depression

Creatine, primarily recognized as a supplement for enhancing strength and muscle performance in athletes, is now piquing the interest of researchers as a potential ally in the fight against depression. A recent systematic review appearing in Brain Medicine sought to understand whether creatine could support the brain's energy requirements, a critical factor in addressing depressive symptoms.

Mixed Results from Clinical Trials

The findings are promising yet decidedly cautious, as they underline the ambiguities surrounding creatine's efficacy. While some trials indicated notable improvements in depressive symptoms, others yielded no tangible benefits, leaving scientists with an open question rather than conclusive insights.

The review, led by Bassam Jeryous Fares from the University of Ottawa, synthesized research from pre-existing studies instead of undertaking new experiments. The review focused on six significant reports encompassing five randomized controlled trials, which involved participants unknowingly receiving either creatine or a placebo.

Trials spanned across various countries, including South Korea, the United States, Brazil, Israel, and India, and collectively involved 238 individuals at their inception—126 were administered creatine, while 112 received a placebo. The average participant age was 36 years, predominantly female, with two studies exclusively enrolling women.

Breakdown of the Trials

Of the five studies reviewed, four targeted individuals diagnosed with major depressive disorder, while one included participants with bipolar disorder undergoing a depressive episode. Due to substantial methodological differences among the studies, the researchers refrained from aggregating data for a unified statistical analysis, opting instead for an individualized assessment of each trial.

In two of the five trials involving women with major depressive disorder, creatine proved to offer significant benefits. One study illustrated that participants consuming five grams of creatine daily alongside the antidepressant escitalopram noticed a more pronounced reduction in depressive symptoms by the eight-week mark compared to those who received escitalopram with a placebo. The results were marked by a Cohen's d of 1.13 on the Hamilton Depression Rating Scale, indicating a substantial improvement in many participants' conditions.

Another trial demonstrated that when creatine was paired with cognitive behavioral therapy, those receiving creatine exhibited a more significant decline in depressive symptoms than the placebo group undergoing therapy.

Conversely, three additional trials did not demonstrate meaningful benefits from creatine supplementation. One study found neither five nor ten grams of creatine daily had any positive effect on individuals with treatment-resistant depression. Another study involving adolescent girls yielded no advantages over the placebo, and a third study among patients with bipolar disorder reported no improvement.

Safety and Variability of Response

Importantly, the review highlighted significant safety concerns. Two participants with bipolar disorder developed hypomania or mania after taking creatine, suggesting that individual responses to creatine could vary, especially based on underlying conditions.

Potential Mechanisms Behind the Observed Effects

Why might creatine influence depression? The premise lies in the brain's immense energy requirements. While commonly associated with rapid energy production in muscles, creatine also plays a vital role in powering the brain cells. Prior research noted alterations in brain creatine metabolism in individuals with mood disorders, prompting investigations into whether energy production disruptions could contribute to depression.

Additionally, creatine may affect levels of specific neurotransmitters such as dopamine and serotonin, both of which are pivotal in mood regulation and targeted by many antidepressants. Yet, these connections remain largely speculative. Current studies reveal correlational data, rather than definitive proof that altered creatine metabolism leads to depression, given the multifaceted nature of the disorder.

Future Research Directions

Fares, who is a student in the Faculty of Medicine at the University of Ottawa, noted, "The signal is interesting, but it is not a verdict." The divergent outcomes from the studies call for caution; as he states, "That is not the kind of evidence on which you change clinical practice." Instead, this encourages further exploration into creatine's potential applications in mental health.

Co-author Nicholas Fabiano, a psychiatry resident at the same university, echoed this sentiment, urging caution regarding the safety and efficacy of creatine. They noted that aside from mild gastrointestinal discomfort, adverse events were limited. However, the current evidence isn't yet compelling enough to warrant regular recommendations for creatine use in treating depression.

The existing trials, characterized by small participant groups and a disproportionate representation of women, have yielded variable quality. Some studies displayed low risk of bias, while others raised concerns primarily related to participant assignment and incomplete data. This variability cautions against broad applicability of the findings.

The review calls for larger and longer clinical trials exceeding eight weeks to validate results, as well as investigations into the effects of combining creatine with exercise and testing different dosages. Interestingly, animal studies hint that creatine's effects on depressive-like behaviors might vary between genders, potentially elucidating the pronounced positive outcomes seen predominantly in the human studies involving women.

Conclusion: Creatine as a Potential Treatment

Currently, creatine emerges as a tantalizing yet unproven treatment option for depression. The longstanding association of creatine with muscle building is now shifting toward research focused on its psychiatric implications, capturing the curiosity of scientists seeking new therapeutic strategies for mental health disorders.

The peer-reviewed research titled "Creatine as a treatment for depression" was published in Brain Medicine and will be available via Open Access starting June 30, 2026.